Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Grows By 6.1%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 46,800 shares, a growth of 6.1% from the November 15th total of 44,100 shares. Based on an average daily volume of 43,900 shares, the days-to-cover ratio is currently 1.1 days. Currently, 2.7% of the company’s shares are short sold.

Avenue Therapeutics Price Performance

ATXI opened at $1.80 on Monday. Avenue Therapeutics has a one year low of $1.60 and a one year high of $26.47. The business has a 50 day simple moving average of $2.05 and a two-hundred day simple moving average of $2.67. The firm has a market capitalization of $3.69 million, a price-to-earnings ratio of 0.10 and a beta of -0.20.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned 1.17% of Avenue Therapeutics at the end of the most recent quarter. 17.34% of the stock is currently owned by institutional investors and hedge funds.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.